Ascletis Announces Positive Preclinical Data for the Most Comprehensive Once-Weekly Oral Peptide Pipeline for the Treatment of Obesity
Ascletis' industry-leading once-weekly oral peptide pipeline covers all four validated targets, with multiple first-in-class fixed-dose combinations. - ASC36o, a once-weekly oral amylin receptor peptide agonist, is the most advanced drug candidate of Ascletis' once-weekly oral peptide pipeline and its Phase I study has started in the U.S. - ASC36o demonstrated a half-life of approximately 7 days and oral bioavailability of 6% to 8% in non-human primates (NHPs), supporting once-weekly oral administration. - Using ASC36o as a cornerstone, Ascletis has developed two first-in-class once-weekly…
Read the full report on Pr Newswire Apac
Story file
- Section
- World
- Topics
- Startups, AI & gadgets, Health alerts
- First reported by
- Pr Newswire Apac
- Reporter
- cision pr newswire
- Published
- Tuesday, 20 October 2026, 5:40 am IST
- Coverage
- One outlet so far
How this page works. The Headline Update lists this report from Pr Newswire Apac with a short summary and a link to the original. The original reporting belongs to the publisher. Spotted an error in our summary? Tell our corrections desk.
